Clinical Trials Logo

Myeloid Leukemia clinical trials

View clinical trials related to Myeloid Leukemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06429449 Not yet recruiting - Leukemia Clinical Trials

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Start date: December 2024
Phase: Phase 1
Study type: Interventional

This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.

NCT ID: NCT05787951 Not yet recruiting - Myeloid Leukemia Clinical Trials

Frequency and Risk Factors of Acute Myeloid Leukemia

Start date: May 1, 2023
Phase:
Study type: Observational

1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital 2. to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

NCT ID: NCT02489929 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Start date: August 2015
Phase: N/A
Study type: Interventional

Myelodysplastic syndrome (MDS) is a group of medical conditions derived from progressive bone marrow failure that result in ineffective production of blood cells. Depending on the severity, MDS reduces the quality of life to the point of being life-threatening. There is a probability of death at all stages of the disease, due to complications and co-morbidities, with progression to acute myeloid leukemia (AML) being the worst evolution. Azacytidine is a nucleosidic analog with original epigenetic mechanism of action that is widely used for treating a variety of myelodysplasic syndromes. Although generally well tolerated, severe and sometimes life-threatening toxicities were unexpectedly observed in some patients. Genetic polymorphism affecting cytidine deaminase (CDA), the liver enzyme responsible for azacytidine detoxification step, could be responsible for poor clinical outcome due to on the one hand to severe toxicities in deficient patients, and on the other hand on treatment failure in ultrametabolizer patients.This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment.